Pulmatrix: The Best Biotech Buyout Target Out There?
(WorldNews Health)

About Pulmatrix Pulmatrix (PULM), is a clinical stage bio-pharmaceutical company which focuses on pulmonary diseases. Pulmatrix has a patented technology called iSPERSE (inhaled small particles easily respirable and emitted). This technology allows patients to easily inhale medication. Source: Pulmatrix Investor Presentation Pulmatrix has multiple drugs in their pipeline: PUR1800 is the most advanced drug in Pulmatrix`s pipeline. This drug is a narrow-spectrum kinase inhibitor (NSKI) which was recently in-licensed from RespiVert. The drug has completed a Phase 2a clinical trial with COPD patients, and it will be reformulated using Pulmatrix`s iSPERSE technology. PUR1900 is an anti-fungal...